Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Endometrial Cancer Incidence and Risk Classification

January 29th 2021

Markman Talks Vilified Vaccines, Taboos, and Treatment for Cervical Cancer

January 28th 2021

Dr. Markman discusses the clinical milestone of the HPV vaccine as a means to prevent cervical cancer, the debate on HPV-negative disease, and what efforts can be done on a global scale to reduce the incidence and mortality of cervical cancer.

Dr. Coleman on the Potential of Tisotumab Vedotin in Cervical Cancer

January 20th 2021

Robert L. Coleman, MD, FACOG, FACS, discusses the potential of tisotumab vedotin in cervical cancer.

HPV-Negative Cervical Cancer: Myth or An Area to Therapeutically Tackle?

January 20th 2021

The idea that HPV-negative cervical cancer is possible, especially in a disease that is mainly driven by HPV positivity, is not a unanimous opinion.

Dr. Markman on Remaining Questions With HPV- Cervical Cancer

January 18th 2021

Maurie Markman, MD, discusses remaining questions regarding human papillomavirus–negative cervical cancer.

Dr. Coleman on Moving Immunotherapy Into Earlier Treatment Lines in Cervical Cancer

January 18th 2021

Robert L. Coleman, MD, FACOG, FACS, discusses the potential to move immunotherapy into earlier lines of treatment in cervical cancer.

Questions Remain Regarding PARP Inhibition in Recurrent Platinum-Sensitive Ovarian Cancer

January 11th 2021

Joshua G. Cohen, MD, FACOG, FACS, discusses the efficacy of PARP inhibitors in ovarian cancer, remaining questions regarding repeat inhibition and treatment duration, and the potential for combinations.

RAF/MEK Inhibitor VS-6766 Plus Defactinib Under Exploration in Recurrent Low-Grade Serous Ovarian Cancer

January 6th 2021

January 6, 2021 — The oral small molecule inhibitor VS-6766, developed by Verastem Oncology, is now under investigation alone and in combination with the FAK inhibitor defactinib in a recently initiated, registration-directed, phase 2 trial in patients with recurrent low-grade serous ovarian cancer.

Boehringer Ingelheim Looks to Expand Targeted Therapies Portfolio

January 5th 2021

January 5, 2020 - Boehringer Ingelheim will add to its cancer cell-directed therapies portfolio with the acquisition of NBE-Therapeutics, the developer of NBE-002, an anti-ROR1 antibody-drug conjugate.

Dr. Corr on the Rationale to Evaluate WNT Inhibition in Gynecologic Cancers

January 4th 2021

Bradley Corr, MD, discusses the rationale to evaluate WNT pathway inhibition in gynecologic cancers.

Future of Advanced Endometrial Cancer

January 4th 2021

Novel Targets for Advanced Endometrial Cancer

January 4th 2021

Endometrial Cancer: Chemo-Free Regimens on the Horizon

January 4th 2021

Emerging Agents: Treatment of Endometrial Cancer

January 4th 2021

Sequencing for Advanced Endometrial Cancer

January 4th 2021

Recurrent Endometrial Cancer: Safety of Combination Therapy

January 4th 2021

Combination Therapy for Recurrent Endometrial Cancer

January 4th 2021

Emerging ICI Therapy for Advanced Endometrial Cancer

January 4th 2021

Immune Checkpoint Inhibitors in Advanced Endometrial Cancer

January 4th 2021

GOG-258 and PORTEC-3 Studies in Endometrial Cancer

January 4th 2021